AML1-ETO-mediated erythroid inhibition: New paradigms for differentiation blockade by a leukemic fusion protein

Critical Reviews in Eukaryotic Gene Expression

Volumn 15, Issue 3, 2005, Pages 207-216

  Choi, Youngjin ^a   Elagib, Kamaleldin E ^a   Goldfarb, Adam N ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

AML; AML1 ETO; Erythroid differentiation; t(8; 21)

Indexed keywords

DNA METHYLTRANSFERASE; HISTONE DEACETYLASE; HYBRID PROTEIN; PROTEIN AML1 ETO; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; AML1 ETO FUSION PROTEIN, HUMAN; AML1-ETO FUSION PROTEIN, HUMAN; GATA1 PROTEIN, HUMAN; ONCOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TRANSCRIPTION FACTOR GATA 1;

ACUTE GRANULOCYTIC LEUKEMIA; CELL DIFFERENTIATION; CHROMOSOME TRANSLOCATION 8; ERYTHROID CELL; ERYTHROPOIESIS; HEMATOPOIESIS; HUMAN; LEUKEMIA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; WILD TYPE; ANIMAL; CELL CULTURE; CHROMOSOME 21; CHROMOSOME 8; CYTOLOGY; GENE TRANSLOCATION; GENETICS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; CORE BINDING FACTOR ALPHA 2 SUBUNIT; ERYTHROID CELLS; ERYTHROPOIESIS; GATA1 TRANSCRIPTION FACTOR; HISTONE DEACETYLASES; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; ONCOGENE PROTEINS, FUSION; SIGNAL TRANSDUCTION; TRANSLOCATION, GENETIC;

EID: 33644908841     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Brunning RD, McKenna RW. Acute myeloid leukemias. In: Tumors of the bone marrow. 1st ed. Washington (DC): Armed Forces Institute of Pathology; 1994. p. 22-100.
2. Peterson LF, Zhang D-E. The 8;21 translocation in leukemogenesis. Oncogene. 2004;23:4255-62.
3. Lutterbach B, Hiebert SW. Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation. Gene. 2000;245:223-35.
4. Bushweller JH. CBF - A biophysical perspective. Semin Cell Dev Biol. 2000;11:377-82.
5. Tracey WD, Speck NA. Potential roles for RUNX1 and its orthologs in determining hematopoietic cell fate. Semin Cell Dev Biol. 2000;11:337-42.
6. Yan J, Liu Y, Lukasik SM, Speck NA, Bushweller JH. CBFβ allosterically regulates the Runx1 Runt domain via a dynamic conformational equilibrium. Nat Struct Mol Biol. 2004;11(9):901-6.
7. Davis JN, McGhee L, Meyers S. The ETO (MTG8) gene family. Gene. 2003;303:1-10.
8. Rhoades KL, Hetherington CJ, Harakawa N, Yergeau DA, Zhou L, Liu L-Q, et al. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood. 2000;96(9):2108-15.
9. Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MAS, Nimer SD. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood. 2002;99(1):15-23.
10. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh E-J, Downing JR. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell. 2002;1:63-74.
11. Hug BA, Lee SYD, Kinsler EL, Zhang J, Lazar MA. Cooperative function of Aml1-ETO corepressor recruitment domains in the expansion of primary bone marrow cells. Cancer Res. 2002;62:2906-12.
12. de Guzman CG, Warren AJ, Zhang Z, Gartland L, Erickson P, Drabkin H, et al. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol. 2002;22(15):5506-17.
13. Schwieger M, Lohler J, Friel J, Scheller M, Horak I, Stocking C. AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency. J Exp Med. 2002;196(9):1227-40.
14. Grisolano JL, O'Neal J, Cain J, Tomasson MH. An activated receptor tyrosine kinase, TEL/PDGFβR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci U S A. 2003;100(16):9506-11.
15. Fenske TS, Pengue G, Mathews V, Hanson PT, Hamm SE, Riaz N, et al. Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice. Proc Natl Acad Sci U S A. 2004;101(42):15184-9.
16. Taj AS, Ross FM, Vickers M, Choudhury DN, Harvey JF, Barber JCK, et al. t(8;21) myelodysplasia, an early presentation of M2 AML. Br J Haematol. 1995;89:890-2.
17. Yamasaki H, Era T, Asou N, Sanada I, Matutes E, Yamaguchi K, et al. High degree of myeloid differentiation and granulocytosis is associated with t(8;21) smoldering leukemia. Leukemia. 1995;9:1147-53.
18. Kojima K, Omoto E, Hara M, Sasaki K, Katayama Y, Nawa Y, et al. Myelodysplastic syndrome with translocation (8;21): a distinct myelodysplastic syndrome entity or M2-acute myeloid leukemia with extensive myeloid maturation? Ann Hematol. 1998;76:279-82.
19. Miyamoto T, Nagafuji K, Akashi K, Harada M, Kyo T, Akashi T, et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood. 1996;87(11):4789-96.
20. Miyamoto T, Weissman IL, Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci U S A. 2000;97(13):7521-6.
21. Nakamura H, Kuriyama K, Sadamori N, Mine M, Itoyama T, Sasagawa I, et al. Morphological subtyping of acute myeloid leukemia with maturation (AML-M2): homogeneous pink-colored cytoplasm of mature neutrophils is most characteristic of AML-M2 with t(8;21). Leukemia. 1997;11:651-5.
22. Kalev-Zylinska ML, Horsfield JA, Flores MVC, Postlethwait JH, Vitas MR, Baas AM, et al. Runx1 is required for zebrafish blood and vessel development and expression of a human RUNX1-CBF2T1 transgene advances a model for studies of leukemogenesis. Development. 2002;129:2015-30.
23. Le XF, Claxton D, Kornblau S, Fan YH, Mu ZM, Chang KS. Characterization of the ETO and AML1-ETO proteins involved in 8;21 translocation in acute myelogenous leukemia. Eur J Haematol. 1998;60(4):217-25.
24. Harada Y, Harada H, Downing JR, Kimura A. A hematopoietic-specific transmembrane protein, Art-1, is possibly regulated by AML1. Biochem Biophys Res Commun. 2001;284:714-22.
25. Tonks A, Pearn L, Tonks AJ, Pearce L, Hoy T, Phillips S, et al. The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells. Blood. 2002;101(2):624-32.
26. Zhang J, Hug BA, Huang EY, Chen CW, Gelmetti V, Maccarana M, et al. Oligomerization of ETO is obligatory for corepressor interaction. Mol Cell Biol. 2001;21:156-63.
27. Amann JM, Nip J, Strom DK, Lutterbach B, Harada H, Lenny N, et al. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol. 2001;21(19):6470-83.
28. Wang J, Saunthararajah Y, Redner RL, Liu JM. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res. 1999;59:2766-9.
29. Klisovic ML, Maghraby EA, Parthun MR, Guimond M, Sklenar AR, Whitman SP, et al. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia. 2003;17:350-8.
30. Elagib KE, Racke FK, Mogass M, Khetawat R, Delehanty LL, Goldfarb AN. RUNX-1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood. 2003;101(11):4333-41.
31. Fossett N, Hyman K, Gajewski K, Orkin SH, Schulz RA. Combinatorial interactions of Serpent, Lozenge, and U-shaped regulate crystal cell lineage commitment during Drosophila hematopoiesis. Proc Natl Acad Sci U S A. 2003;100(20):11451-6.
32. Waltzer L, Ferjoux G, Bataille L, Haenlin M. Cooperation between the GATA and RUNX factors Serpent and Lozenge during Drosophila hematopoiesis. EMBO J. 2003;22(24):6516-25.
33. Choi Y, Elagib KE, Goldfarb AN. Erythroid inhibition by AML1-ETO: repression of GATA-1 function by a novel non-transcriptional mechanism involving targeted protein degradation. Blood. 2004;104(11):114a.
34. Gurbuxani S, Vyas P, Crispino JD. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood. 2004;103(2):399-406.
35. Vangala RK, Heiss-Neumann MS, Rangatia JS, Singh SM, Schoch C, Tenen DG, et al. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood. 2003;101(1):270-77.
36. Zhang J, Kalkum M, Yamamura S, Chait BT, Roeder RG. E protein silencing by the leukemogenic AML1-ETO fusion protein. Science. 2004;305:1286-9.
37. Muller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S, et al. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol. 2004;24(7):2890-904.
38. Alcalay M, Meani N, Gelmetti V, Fantozzi A, Fagioli M, Orleth A, et al. Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest. 2003;112(11):1751-61.
39. Elsasser A, Franzen M, Kohlmann A, Weisser M, Schnittger S, Schoch C, et al. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner. Oncogene. 2003;22:5646-57.
40. Cadigan K, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev. 1997;11:3286-305.
41. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature. 2004;432:324-31.
42. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature. 2003;423:409-14.
43. Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T, et al. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature. 2003;423:448-52.
44. Van Den Berg DJ, Sharma AK, Bruno E, Hoffman R. Role of members of the Wnt gene family in human hematopoiesis. Blood. 1998;92(9):3189-202.
45. Moore A, Tahinci E, Lee E, Hiebert SW. RUNX1-ETO stimulates Wnt signaling by inhibiting the function of ETO family member proteins. Blood. 2004;104(11):700a.
46. Vercauteren SM, Sutherland HJ. Constitutively active Notch4 promotes early human hematopoietic progenitor cell maintenance while inhibiting differentiation and causes lymphoid abnormalities in vivo. Blood. 2004;104(8):2315-22.
47. Carlesso N, Aster JC, Sklar J, Scadden DT. Notch1-induced delay of human hematopoietic progenitor cell differentiation is associated with altered cell cycle kinetics. Blood. 1999;93(3):838-48.
48. Han W, Ye Q, Moore MAS. A soluble form of human Delta-like-1 inhibits differentiation of hematopoietic progenitor cells. Blood. 2000;95(5):1616-25.
49. Lam LT, Ronchini C, Norton J, Capobianco AJ, Bresnick EH. Suppression of erythroid but not megakaryocytic differentiation of human K562 erythroleukemic cells by Notch-1. J Biol Chem. 2000;275 (26):19676-84.
50. Kumano K, Chiba S, Shimizu K, Yamagata T, Hosoya N, Saito T, et al. Notch1 inhibits differentiation of hematopoietic cells by sustaining GATA-2 expression. Blood. 2001;98(12):3283-9.
51. Hadland BK, Huppert SS, Kanungo J, Xue Y, Jiang R, Gridley T, et al. A requirement for Notch1 distinguishes 2 phases of definitive hematopoiesis during development. Blood. 2004;104(10):3097-105.
52. Elagib KE, Xiao M, Hussaini IM, Delehanty LL, Palmer LA, Racke FK, et al. Jun blockade of erythropoiesis: role for repression of GATA-1 by HERP2. Mol Cell Biol. 2004;24(17):7779-94.
53. Back J, Dierich A, Bronn C, Kastner P, Chan S. PU.1 determines the self-renewal capacity of erythroid progenitor cells. Blood. 2004;103(10):3615- 23.
54. Scott EW, Simon MC, Anastasi J, Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science. 1994;265:1573-7.
55. Xu Z, Huang S, Chang LS, Agulnick AD, Brandt SJ. Identification of a TAL1 target gene reveals a positive role for the LIM domain-binding protein Ldb1 in erythroid gene expression and differentiation. Mol Cell Biol. 2003;23(21):7585-99.
56. Lahlil R, Lecuyer E, Herblot S, Hoang T. SCL assembles a multifactorial complex that determines glycophorin A expression. Mol Cell Biol. 2004;24(4):1439-52.
57. Cai Y, Xu Z, Xie J, Koury MJ, Hiebert SW, Brandt SJ. Proteomic identification of TAL1/SCL-interacting proteins: ETO-2 and MTGR1 interact with TAL1 in erythroid progenitors. Blood. 2004;104(11):105a.
58. Schuh AH, Hamlett I, Strouboulis J, Grosveld F, Vyas P, Porcher C. The oncoprotein SCL/Tal-1 associates with the co-repressor ETO-2 in multi-protein complexes in erythroid cells and megakaryocytes. Blood. 2004;104(11):759a.